USFDA completes inspection of Lupin’s Nagpur facility
13th Jan 2020

United States Food and Drug Administration (USFDA) has completed a Prior Approval Inspection (PAI) at Lupin’s Nagpur oral solid dosage manufacturing facility. The inspection was carried out between January 6, 2020 and January 10, 2020. The inspection closed with two 483 observations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.